Board of Directors

Camille L. Bedrosian, M.D., has served on Crinetics board of directors since September 2020. Dr. Bedrosian serves on the Research and Development Committee, which she chairs, the Nominating and Corporate Governance Committee and the Global Therapeutics Strategy and Access Committee.

Since November 2023, Dr. Bedrosian has served as Chief Medical Officer for Amylyx Pharmaceuticals, Inc. From 2018 through 2023, Dr. Bedrosian served as Executive Vice President and Chief Medical Officer at Ultragenyx Pharmaceutical Inc. Dr. Bedrosian also served as Strategic Development Advisor at Ultragenyx, where she provided strategic guidance to the clinical development and translational research programs. Dr. Bedrosian previously served as Senior Vice President and Chief Medical Officer at Alexion Pharmaceuticals, Inc., a biopharmaceutical company, from May 2008 to January 2018. Between September 2002 and April 2008, she served as Vice President and Chief Medical Officer at Ariad Pharmaceuticals, Inc., an oncology company. From 1997 to 2002, Dr. Bedrosian served in the Clinical Research and Development Department of Wyeth/Genetics Institute, Inc., most recently as Senior Director, Oncology/Hematology.

From 1986 to 1997, she was a Fellow, an Associate and then Assistant Professor of Medicine in the Division of Hematology and Oncology at Duke University Medical Center and the Duke Comprehensive Cancer Center. From 2020 to 2025, Dr. Bedrosian served as a member of the board of directors of Rhythm Pharmaceuticals, Inc., a publicly traded biopharmaceutical company. Dr. Bedrosian received her bachelor’s degree from Harvard University in Chemistry, where the school awards an A.B. degree, her master’s degree in biophysics from M.I.T. and her medical degree from Harvard Medical School. Dr. Bedrosian’s extensive leadership experience in the life science industry, in rare disease drug development and with global regulatory matters contributed to our board of directors’ conclusion that she should serve as a director of our company.